207 related articles for article (PubMed ID: 33647972)
1. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma.
Brown PD; Chung C; Liu DD; McAvoy S; Grosshans D; Al Feghali K; Mahajan A; Li J; McGovern SL; McAleer MF; Ghia AJ; Sulman EP; Penas-Prado M; de Groot JF; Heimberger AB; Wang J; Armstrong TS; Gilbert MR; Guha-Thakurta N; Wefel JS
Neuro Oncol; 2021 Aug; 23(8):1337-1347. PubMed ID: 33647972
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme.
Monjazeb AM; Ayala D; Jensen C; Case LD; Bourland JD; Ellis TL; McMullen KP; Chan MD; Tatter SB; Lesser GJ; Shaw EG
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):743-8. PubMed ID: 21236604
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
4. Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme.
Chen YD; Feng J; Fang T; Yang M; Qiu XG; Jiang T
Chin Med J (Engl); 2013 Jun; 126(12):2320-4. PubMed ID: 23786946
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy-GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study.
König L; Jäkel C; von Knebel Doeberitz N; Kieser M; Eberle F; Münter M; Debus J; Herfarth K
Radiat Oncol; 2021 Dec; 16(1):240. PubMed ID: 34930368
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
[TBL] [Abstract][Full Text] [Related]
9. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
10. Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Kong L; Gao J; Hu J; Lu R; Yang J; Qiu X; Hu W; Lu JJ
Cancer Commun (Lond); 2019 Feb; 39(1):5. PubMed ID: 30786916
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment.
Al Feghali KA; Randall JW; Liu DD; Wefel JS; Brown PD; Grosshans DR; McAvoy SA; Farhat MA; Li J; McGovern SL; McAleer MF; Ghia AJ; Paulino AC; Sulman EP; Penas-Prado M; Wang J; de Groot J; Heimberger AB; Armstrong TS; Gilbert MR; Mahajan A; Guha-Thakurta N; Chung C
Neurooncol Adv; 2021; 3(1):vdab073. PubMed ID: 34337411
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial.
Giordano FA; Brehmer S; Mürle B; Welzel G; Sperk E; Keller A; Abo-Madyan Y; Scherzinger E; Clausen S; Schneider F; Herskind C; Glas M; Seiz-Rosenhagen M; Groden C; Hänggi D; Schmiedek P; Emami B; Souhami L; Petrecca K; Wenz F
Neurosurgery; 2019 Jan; 84(1):41-49. PubMed ID: 29528443
[TBL] [Abstract][Full Text] [Related]
15. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme.
Fuller CD; Choi M; Forthuber B; Wang SJ; Rajagiriyil N; Salter BJ; Fuss M
Radiat Oncol; 2007 Jul; 2():26. PubMed ID: 17629934
[TBL] [Abstract][Full Text] [Related]
16. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results.
Narayana A; Yamada J; Berry S; Shah P; Hunt M; Gutin PH; Leibel SA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):892-7. PubMed ID: 16458777
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
19. Radiation-induced acute toxicities after image-guided intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for patients with spinal metastases (IRON-1 trial) : First results of a randomized controlled trial.
Sprave T; Verma V; Förster R; Schlampp I; Bruckner T; Bostel T; Welte SE; Tonndorf-Martini E; El Shafie R; Nicolay NH; Debus J; Rief H
Strahlenther Onkol; 2018 Oct; 194(10):911-920. PubMed ID: 29978307
[TBL] [Abstract][Full Text] [Related]
20. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
